Vinpocetine - instructions for use, dose, side effects, contraindications

Excipients: lactose monohydrate (sugar milk) - 0.2074 g, potato starch - 0.0291 g, povidone (polyvinylpyrrolidone) 0.006 g, magnesium stearate 0.0025 g

Description:Tablets are white or white with a yellowish hue of color, a flat-cylindrical shape with a facet and a risk.

Pharmacotherapeutic group:Cerebral blood flow improver

ATX: & nbsp

N.06.B.X.18 Vinpocetine

Pharmacodynamics:

Vinpocetine selectively inhibits the potentiated sodium (Na⁺) channels, causing a dose-dependent decrease in the concentration of calcium ions (Ca²⁺) in the endings of the neurons of the striatum. It is believed that the reduction in current Na⁺ has a neuroprotective effect due to a decrease in excitotoxicity and a weakening of neuronal damage caused by cerebral ischemia or reperfusion.

Vinpocetine increases the concentration of 3,4-dihydroxyphenylacetic acid (dopamine metabolite) in the nerve endings of the striatum. This action is similar to the pharmacological action of reserpine (reminiscent of the chemical structure vinpocetine), which depletes the supplies of catecholamines in the nerve endings of the brain, which causes side effects from the cardiovascular system and the antipsychotic effect.

It also inhibits phosphodiesterase type 1 (PDE-1), which leads to an increase in the concentration of intracellular cyclic guanosine monophosphate (cGMP). This leads to a relaxation of the smooth muscles of the cerebral vessels

Pharmacokinetics:

When ingested quickly and completely absorbed in the gastrointestinal tract (mainly in the proximal parts of the small intestine). Bioavailability when taken on an empty stomach - about 7%. Time to reach the maximum concentration (TCmax) in blood plasma - 1 hour, in tissues - 2-4 hours. When passing through the wall of the intestine is not exposed to metabolism.When introducing repeated doses, the kinetics is linear.

The connection with plasma proteins - 66%, clearance - 66.7 l / h, exceeds the hepatic clearance (50 l / h), which indicates extrahepatic metabolism. Penetrates into breast milk (0.25% within 1 hour), through the placental barrier. The half-life (T1 / 2) is 3.54 - 6.12 hours. It is excreted by the kidneys and intestines in the ratio 3: 2.

Indications:

Neurology (with the composition of complex therapy): as a symptomatic agent for various forms of cerebral circulatory insufficiency (ischemic stroke, restorative stage of hemorrhagic stroke, the consequences of a stroke, transient ischemic attack, vascular dementia, circulatory failure in the vertebrobasilar pool, cerebral atherosclerosis, posttraumatic and hypertensive encephalopathy); ophthalmology: chronic vascular diseases of the choroid and retina (including Occlusion of the central artery or vein of the retina); a decrease in the severity of perceptual hearing, Meniere's disease, idiopathic tinnitus.

Contraindications:Hypersensitivity, an acute phase of hemorrhagic stroke,severe coronary heart disease, severe heart rhythm disturbances, pregnancy, lactation, age under 18, lactose intolerance, lactase deficiency, glucose-galactose malabsorption.

Carefully:Be careful when prescribing Vinpocetine for patients taking antihypertensive drugs or drugs that extend the QT interval (loratadine, terfenadine, erythromycin, probucol).

Pregnancy and lactation:Vinpocetine contraindicated in pregnancy. If it is necessary to use it during lactation, breastfeeding should be stopped.

Dosing and Administration:

Inside, after eating.

The initial dose is 15 mg / day, the standard daily dose is 5-10 mg 3 times a day. The maximum daily dose is 30 mg.

Course of treatment -1-3 months. Before cancellation, the dose should be gradually reduced.

Side effects:

From the cardiovascular system: changes in the electrocardiogram (depression of the ST segment, prolongation of the Q-T interval); tachycardia, extrasystole (cause-and-effect relationship not established), lability of blood pressure (more often decrease)

From the central nervous system: sleep disturbance (insomnia, increased drowsiness); dizziness, headache, general weakness (may be a manifestation of the underlying disease).

From the digestive system: dryness of the oral mucosa, nausea, heartburn.

Other: skin allergic reactions, increased sweating, skin hyperemia.

If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, tell your doctor.

Overdose:

Symptoms of intoxication are nonspecific. Initially, nausea, dizziness, tachycardia, lowering of blood pressure are possible; further - arrhythmias in the form of ventricular extrasystoles, blockades, in severe cases - arrhythmia of the type "pirouette".

Treatment: drug withdrawal, gastric lavage, reception of activated charcoal, symptomatic treatment.

Interaction:It is possible to intensify the hypotensive effect with simultaneous application with methyldopa (blood pressure control is necessary).

Special instructions:

Use in persons with impaired liver and kidney function: Vinpocetine does not have a nephro- and hepatotoxic effect, when the drug is prescribed for patients with a violation of the liver and kidneys, dose adjustment is not required.

In the case of the initial prolongation of the Q-T interval, as well as simultaneous use with drugs extending the Q-T interval, periodic monitoring of the electrocardiogram is necessary during the treatment with Vinpocetine.

Effect on the ability to drive transp. cf. and fur:During the treatment period it is necessary to refrain from driving motor vehicles and practicing potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions.

Form release / dosage:Tablets of 5 mg.

Packaging:

For 10 tablets in a contour mesh box made of polyvinylchloride film and aluminum foil printed lacquered.

By 20, 30, 40, 50, 60, 80, 100 tablets in cans of polymeric.

Each bank or 1, 2, 3, 4, 5 contour squares with instructions for use are placed in a cardboard pack.

Storage conditions:

In dry, dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

2 years.

Do not use after the expiration date.

Terms of leave from pharmacies:On prescription

Registration number:LS-000801

Date of registration:31.10.2011 / 21.01.2016

Expiration Date:Unlimited

The owner of the registration certificate:URALBIOFARM, OJSC URALBIOFARM, OJSC Russia

Manufacturer: & nbsp

URALBIOFARM, OJSC Russia

Information update date: & nbsp18.02.2017

Illustrated instructions

Instructions

Vinpocetine (Vinpocetine)